Search research articles
Contact Us
Filters
Showing results (531-540 of 567) with videos related to
Page
of 57
Sort By:
Nature Medicine
|
May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
David A Braun, Yue Hou, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Toni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Frontiers in Water
|
June 10, 2024
A one health approach for monitoring antimicrobial resistance: developing a national freshwater pilot effort
Alison M Franklin, Daniel L Weller, Lisa M Durso, et al.
Nature Reviews. Clinical Oncology
|
August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2016
International cancer seminars: a focus on kidney cancer
G Scelo, J N Hofmann, R E Banks, et al.
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 57
Search research articles
Search
Showing results (531-540 of 567) with videos related to
Sort By:
Page
of 57
Nature Medicine
|
May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
David A Braun, Yue Hou, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Toni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Frontiers in Water
|
June 10, 2024
A one health approach for monitoring antimicrobial resistance: developing a national freshwater pilot effort
Alison M Franklin, Daniel L Weller, Lisa M Durso, et al.
Nature Reviews. Clinical Oncology
|
August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2016
International cancer seminars: a focus on kidney cancer
G Scelo, J N Hofmann, R E Banks, et al.
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 57